Generation of new pancreatic beta cells

• US 9,133,440 B2
• Filed: 10/26/2012
• Issued: 09/15/2015
• Est. Priority Date: 09/27/2012
• Status: Active Grant

• Current Assignee: Claresa Levetan
• Original Assignee: Perle Bioscience, Inc.
• Inventors: Levetan, Claresa
• Primary Examiner(s): Landau, Sharmila G.
• Assistant Examiner(s): Barron, Sean C
• Application Number:
  US13/662,253
• Publication Number:
  US 20140120064A1
• Time in Patent Office: 1,054 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 35/39 Pancreas; Islets of Langerhans Langerhans cells of epidermis A61K35/36
• CPC Class Codes: C07K 14/07 Vaccinia virus; Variola virus
• CPC Class Codes: C07K 14/435 from animals; from humans
• CPC Class Codes: C12N 2501/998 Proteins not provided for elsewhere
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue. This invention identifies a specific binding region of the Reg Receptor from which peptidomimetics and stimulating antibodies have been developed for the generation of new beta cells which may be administered directly to patients with said conditions including type 1 diabetes, type 2 diabetes, PreDiabetes and other conditions of beta cell deficiency, and provides specific methodology for protecting new beta cells generated for usage in type 1 diabetes and Latent Autoimmune Diabetes of Adulthood. This invention also provides for ex-vivo generation and delivery of beta cells utilizing the inventions described within.

Claims

1. A method for the generation of new beta cells from pancreatic extra-islet ductal tissue, comprising the steps of:

a. culturing pancreatic extra-islet ductal tissue ex vivo; and

b. contacting said pancreatic extra-islet ductal tissue with a peptide, wherein the peptide consists of an amino acid sequence selected from the group consisting of NVWIGLHDP (SEQ ID NO;

1), VWIGLHDP (SEQ ID NO;

4), and WIGLHDP (SEQ ID NO;

7) and has direct Reg receptor binding activity, and wherein the amount of agent is effective for forming beta cells from said pancreatic extra-islet ductal tissue.

2. The method of claim 1, wherein the pancreatic islet ductal tissue includes progenitor cells.

3. A method of treating a condition that is associated with or is a risk factor for impaired glucose homeostasis comprising the steps of:

a. culturing pancreatic extra-islet ductal tissue ex vivo;

b. contacting said pancreatic extra-islet ductal tissue with a peptide, wherein the peptide consists of an amino acid sequence selected from the group consisting of NVWIGLHDP (SEQ ID NO;

1), VWIGLHDP (SEQ ID NO;

4), and WIGLHDP (SEQ ID NO;

7) and has direct Reg receptor binding activity, and wherein the amount of agent is effective for forming beta cells from said pancreatic extra-islet ductal tissue;

c. administering said beta cells to the patient.

4. The method of claim 3, wherein the pancreatic islet ductal tissue includes progenitor cells.

5. The method of claim 3, wherein the beta cells are administered to the subject through an oral, intravenous, subcutaneous, or intra-arterial route of administration.

6. The method of claim 3, wherein the beta cells are delivered through the umbilical vein, portal vein, or hepatic artery.

7. The method of claim 3, wherein the beta cells are delivered directly to the pancreas or the liver.

8. The method of claim 3, wherein the condition is associated with autoimmunity and an immune modulator is administered before and/or in parallel with the administration of the beta cells.

9. The method of claim 8, wherein the immune modulator is a general immunosuppressant agent or an antibody targeted to lymphocytes.

10. The method of claim 8, wherein the immune modulator is Cyclosporine.